Shentu J

ORCID: 0000-0002-7293-9768 · 2 papers in corpus · active 2024
2024
Therapeutic advances in medical oncology ·doi:10.1177/17588359241307818

BackgroundA newly generic microspheres, sustained-release formulation of triptorelin acetate 3.75 mg has been developed.ObjectivesTo evaluate the efficacy, pharmacokinetics, and safety of triptorelin 1-month formulation in Chinese patients …

2024
Drug design, development and therapy ·doi:10.2147/dddt.s460681

PurposeEstradiol valerate (Progynova®) is used as hormone therapy to supplement estrogen deficiency. This study aimed to assess the bioequivalence of an estradiol valerate tablet and its generic form, under fasting and fed conditions.Method…